预约演示
Sudo secures additional funds to advance TYK2 inhibitorsTYK2 inhibitors to clinic
2024-02-14
临床2期
Sudo will advance its TYK2 inhibitors into clinical trials to treat patients with neurodegenerative and dermatologic diseases. Credit: Pressmaster / Shutterstock.com.
Sudo Biosciences has sTYK2 inhibitorsTYK2ed an additional $30m in its second round of Series B funeurodegenerative and dermatologic diseasesrosine kinase 2 (TYK2) inhibitors into clinic.
Sudo Biosciencescing includes contributions from new investors: the SV Health Investors Fund, the Dementia Discovery Fund, tyrosine kinases anTYK2aps by Bayer.
The Series B round was led by Enavate Sciences and TPG, with participation from a cohort of investDementiauding Sanofi VentUPMC Enterprisesfe Science anBayerveyor Capital.
This investment brings the funds raised in this rouTPGto a total of $147m and the overall funding since the compSanofi Ventures to $188m.
The funds will be directed towards advancing two investigational TYK2 candidates into the clinic in 2024.
See Also:Latigo secures $135m for non-opioid pain drug developmenTYK2
BioAge seLatigo$170m for obesity therapeutics development
Sudo’s pipeline targets the TYK2 pseudokinase domain, with a focus on developing treatments for multiple sclerosis, neurodegenerative diseases and immune-mediated dermatologic diseases.
Both TYK2 inhibitor candidates will enter clinical trials in 2024.
Sudo Biosciences CEO Scott Byrd stated: “We are pleased to welcome these new investors as they emultiple sclerosistrneurodegenerative diseases meanimmune-mediated dermatologic diseasescision TYK2 inhibitors into clinic.
“ThiTYK2 inhibitorsTYK2rther funding enhances our ability to optimise the develomultiple sclerosisine pneurodegenerative diseasesneuroinflammation
SV HeTYK2 inhibitorTYK2 Investors partner Jonathan Behr stated: “We are happy to partner with Sudo on the Series B second closing and be a catalyst to enable the company to generate clinical data with these potential first and best-in-class brain-penetrant TYK2 inhibitors in multiple neuroinflammatory diseases. Specifically, we see scope to expand beyond MS into Alzheimer’s and ALS.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。